The benefit of associating anti-CD38 monoclonal antibodies to proteasome inhibitor (PI)/immunomodulatory agent (IA) and dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma (MM) remains unclear. PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials that investigated the addition of anti-CD38 monoclonal antibodies to a therapy composed of PI/IA and dexamethasone versus PI/IA and dexamethasone alone for treating relapsed or refractory MM. Hazard ratios (HRs) or risk ratios (RRs) were computed for binary endpoints, with 95% confidence intervals (CIs). Six studies comprising 2191 patients were included. Anti-CD38 monoclonal antibody significantly improved progression-free survival (HR 0.52; 95% CI 0.43-0.61; < 0.001) and overall survival (HR 0.72; 95% CI 0.63-0.83; < 0.001). There was a significant increase in hematological adverse events, such as neutropenia (RR 1.41; 95% CI 1.26-1.58; < 0.01) and thrombocytopenia (RR 1.14; 95% CI 1.02-1.27; = 0.02), in the group treated with anti-CD38 monoclonal antibody. Also, there was a significant increase in non-hematological adverse events, such as dyspnea (RR 1.72; 95% CI 1.38-2.13; < 0.01) and pneumonia (RR 1.34; 95% CI 1.13-1.59; < 0.01), in the group treated with anti-CD38 monoclonal antibody. In conclusion, the incorporation of an anti-CD38 monoclonal antibody demonstrated a promising prospect for reshaping the established MM treatment paradigms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11051236 | PMC |
| http://dx.doi.org/10.3390/jpm14040360 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba.
J Oncol Pharm Pract
January 2025
CancerCare Manitoba, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.
Introduction: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of myeloma and other related disorders. To mitigate the risk of infusion related reactions with IV Daratumumab the product monograph suggested a slow administration schedule that extends over several hours. This leads to a significant burden for the outpatients' treatment administration units and indirect costs to the patients such as time toxicity.
View Article and Find Full Text PDFIberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse.
Br J Haematol
January 2025
Service d'hématologie, Centre Hospitalo-Universitaire, Nantes, France.
Most transplant-ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti-CD38 monoclonal antibody at first relapse and represent a difficult-to-treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.
View Article and Find Full Text PDFComprehensive safety evaluation of isatuximab in multiple myeloma using disproportionality analysis of FAERS and meta-analysis of randomized controlled trials.
Sci Rep
December 2024
Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar (Mohali), Punjab, India.
Article Synopsis
- Isatuximab is an anti-CD38 monoclonal antibody effective in treating both relapsed/refractory and newly diagnosed multiple myeloma (MM), showing the ability to induce cell death (apoptosis) in MM cells.
- This study examines the safety profile of isatuximab through two main methods: analyzing adverse event data from the FDA Adverse Event Reporting System (FAERS) and conducting a meta-analysis of randomized controlled trials (RCTs) with a focus on reported adverse events (AEs).
- Results indicate the isatuximab group had a higher incidence of significant AEs, particularly grade three or higher neutropenia and thrombocytopenia, compared to
Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives.
Clin Lymphoma Myeloma Leuk
November 2024
Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany. Electronic address:
Despite significant advancements, multiple myeloma (MM) remains incurable, and there is still a pressing need for new therapeutic strategies with highly selective mechanisms of action and balanced off-target toxicity. In recent years, the development of "off-the-shelf" bispecific antibodies (bsAbs) has significantly enhanced our ability to treat relapsed or refractory MM. Teclistamab, elranatamab (both BCMA × CD3), and talquetamab (GPRC5D × CD3) are approved for treating MM patients who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.
View Article and Find Full Text PDFTreatment of elderly and frail myeloma patients.
Presse Med
December 2024
Department of Oncology, McMaster University, Hamilton, Ontario, Canada. Electronic address:
Multiple myeloma (MM) is an incurable cancer of older adults. Given the aging population, the prevalence of older adults with MM is expected to further increase over the next decade. Challenges in treating older adults result from the heterogeneity of both aging itself and the disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!